Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
ChinaIPO:
12 June 1996Next earnings report:
20 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:59:23 GMTDividend
Analysts recommendations
Institutional Ownership
CASI Latest News
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
What type of business is CASI Pharmaceuticals?
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
What sector is CASI Pharmaceuticals in?
CASI Pharmaceuticals is in the Healthcare sector
What industry is CASI Pharmaceuticals in?
CASI Pharmaceuticals is in the Biotechnology industry
What country is CASI Pharmaceuticals from?
CASI Pharmaceuticals is headquartered in China
When did CASI Pharmaceuticals go public?
CASI Pharmaceuticals initial public offering (IPO) was on 12 June 1996
What is CASI Pharmaceuticals website?
https://www.casipharmaceuticals.com
Is CASI Pharmaceuticals in the S&P 500?
No, CASI Pharmaceuticals is not included in the S&P 500 index
Is CASI Pharmaceuticals in the NASDAQ 100?
No, CASI Pharmaceuticals is not included in the NASDAQ 100 index
Is CASI Pharmaceuticals in the Dow Jones?
No, CASI Pharmaceuticals is not included in the Dow Jones index
When does CASI Pharmaceuticals report earnings?
The next expected earnings date for CASI Pharmaceuticals is 20 August 2024